TEVA Q4 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B-2.0% YoY

Gross Profit

$2.0B43.8% margin

Operating Income

$148M3.3% margin

Net Income

$109M2.4% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

$538M

Free Cash Flow

$419M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$57.5B

Total Liabilities

$42.4B

Stockholders' Equity

$14.0B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$4.6B	-2.0%
Gross Profit	$2.0B	$2.0B	-0.7%
Operating Income	$148M	-$3.2B	+104.7%
Net Income	$109M	-$2.9B	+103.8%

Revenue Segments

Other Activities

$332M77%

International Markets

$101M23%

Geographic Segments

North America

$1.9B100%

Europe

$7M0%